Results from real-world data and post-hoc analysis of Novartis Beovu® pivotal trials presented at AAO 2020

  • Initial findings on patient characteristics and event likelihood provide insights related to Beovu use in wet AMD1,2
     
  • Follows establishment of multi-disciplinary expert coalition and Novartis commitment to sharing data and findings with ophthalmology community
     
  • Despite existing therapies, significant unmet need still exists for wet AMD patients; data shows around half of patients have unresolved fluid, with a third requiring monthly injections3,4             

Basel, November 13, …

/by

New Novartis analyses for investigational inclisiran demonstrate consistently effective and sustained LDL-C reduction at month 17 regardless of age and gender

  •  Pooled data analyses from Phase III ORION-9, -10 and -11 showed that inclisiran consistently reduced low-density lipoprotein cholesterol (LDL-C) by approximately 51% in both male and female adult patients and in three age categories1,2

  • Sustained LDL-C reduction with inclisiran was observed regardless of age or gender differences1,2 with two doses a year, after an initial dose and then again at three months; the overall …
/by

Study suggests there may be two stages of fatal lung disease in COVID-19

Cell samples from COVID19 lung tissue analysis

Translational immunologists from the Novartis Institutes for BioMedical …

/by

Novartis provides update on CAN-COVID trial in hospitalized patients with COVID-19 pneumonia and cytokine release syndrome (CRS)

  • The Phase III trial investigating canakinumab plus standard of care (SoC) did not meet its primary endpoint of a greater chance of patient survival without the need for invasive mechanical ventilation, or its key secondary endpoint of reduced COVID-19 mortality, compared with SoC1

  • Ilaris® (canakinumab) remains an effective …
/by

Novartis Cosentyx® shows early synovitis reduction in patients with psoriatic arthritis in first-of-its-kind study

  • Significant reduction of synovitis (joint lining inflammation) was demonstrated with Cosentyx®  at Week 12  vs. placebo, with improvements as early as Week 11
     
  • ULTIMATE is the first ever Phase IIIb imaging study primarily looking at the time course of response to Cosentyx in biologic-naïve patients with active psoriatic arthritis (PsA) using Power Doppler ultrasonography (PDUS)1
     
  • PDUS is a sensitive technology, allowing detection and monitoring of early changes in synovitis and enthesitis1 …
/by

Need for new heart disease medicines drives wave of potential therapies

If you took all the people on Earth with atherosclerosis and moved them to a single country, it would be the most populous nation on the planet. Those relocated would wonder why they were chosen, because their condition – caused by high cholesterol – is invisible.

It is also potentially deadly.

Atherosclerosis, caused by a buildup of cholesterol that forms plaques in arteries, increases the risk of cardiovascular disease, such as a heart attack and stroke. Despite the availability of approved medicines, heart disease remains the No. 1 cause of death by chronic disease worldwide …

/by

Novartis announces positive results from a Phase IV study showing superior tolerability and efficacy of Aimovig® (erenumab) compared with topiramate in migraine prevention

  • The first randomized, double blind, head-to-head study of Aimovig® (erenumab) against topiramate in patients with episodic and chronic migraine (HER-MES) achieved superiority in its primary and secondary endpoints
  • Aimovig showed superior tolerability and efficacy against topiramate and provided a significant reduction in monthly migraine days (MMDs)
  • Aimovig is the most prescribed anti-calcitonin gene-related peptide pathway (anti-CGRP) …
/by

Novartis sickle cell medicine Adakveo® approved in Europe to prevent recurrent vaso-occlusive crises

  • Adakveo is the first targeted sickle cell disease therapy for prevention of recurrent vaso-occlusive crises (VOCs) available for use in Europe
  • Clinical data showed that use of Adakveo led to a significant reduction in the rate of VOCs and to fewer days spent in hospital
  • VOCs disrupt patients’ lives physically, socially, and emotionally – and can increase risk of organ damage and early death

Basel, October 30, …

/by

Novartis expands Kymriah® manufacturing footprint with first-ever approved site for commercial CAR-T cell therapy manufacturing in Asia

  • Foundation for Biomedical Research and Innovation (FBRI) in Kobe, Japan becomes first CAR-T cell therapy commercial manufacturing site in Asia
     
  • Novartis global CAR-T manufacturing footprint now spans four continents, bringing Kymriah closer to patients and healthcare professionals around the world
     
  • Prestigious FBRI is recognized for its world-class expertise and established practice in CAR-T cell therapy
     
  • Global CAR-T manufacturing growth includes recent FDA approval for further capacity expansion in the US, …
/by

Novartis presents latest Phase III data reinforcing Cosentyx® as a first-line systemic treatment in pediatric psoriasis

  • Latest data show Cosentyx® provides fast and strong skin clearance, significant improvement in quality of life and a favorable safety profile1,2
     
  • Moderate-to-severe psoriasis affects more than 350,000 children worldwide3, with the physical and psychological burden disrupting important formative years4
     
  • FDA has accepted a submission for Cosentyx in moderate-to-severe plaque psoriasis in children and adolescents aged 6 to <18 years
     
  • Cosentyx is backed …
/by